Rockwell Medical (RMTI)

Russell Ellison President and CEO
Russell Skibsted EVP, CFO and Chief Business Officer
Marc Hoffman CMO
Tim Chole VP, Marketing
Claudia Styslinger IR, Argo Partners
Brandon Folkes Cantor Fitzgerald
Raghuram Selvaraju H.C. Wainwright
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.

Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical 2020 Q3 Results Call.

As a reminder, this conference call is being recorded. At this time, I would like to introduce Claudia Styslinger, IR. Please go ahead.

Claudia Styslinger

Welcome to Rockwell Medical's third quarter 2020 earnings results call. of the Styslinger for Relations Claudia Medical. Rockwell is Argo Investor Partners, representative This

Rockwell today's Dr. joining Skibsted, Medical Russell from President will Chief me Joining on be Chole, Tim Chief and Chief Officer Vice Executive Medical Business President, who Officer; Ellison, Marketing; call Q&A. Chief Officer; Hoffman, Vice us Russell and for Executive of Financial and Marc President Dr. are Officer

statements will I not begin, that to future the expressions discuss federal expectations are may might, forecast, the intent, wanted forward-looking potential, based such predict, Medical's limited current intention Rockwell’s believe, or Words but belief we we Before plan, to Dialysate, or continue, certain platform. as will, securities constitute any commercialize note and or within Rockwell including, intend statements could, products project, of meaning may, regarding Triferic matters similar ferric expect, upon laws, AVNU forward-looking Triferic pyrophosphate should, anticipate, statements. estimate, to,

can which could Actual subject not should beyond and estimates change. set of different. assumptions SEC forward-looking of as our accessed various current alter to While statements, forward-looking obligation on placed those this on Medical's on on forward-looking November upon uncertainties, materially control like Rockwell release future or are new inherent statements. Russell? Relations be whether based law. time, call these forward-looking as of for same Executive Investor which subject results Rockwell Web be statements, us except being is Medical Rockwell reliance the audio and call the Ellison. should to any are At Officer, without Medical's or accessed result expressly any such on Dr. These conference by Accordingly, based conference and otherwise, to be date many subject to X, Chief Web page. statements the undue information, are reliance events place which and This a on required filings, limitation, are update and Medical Russell undue uncertainty. this to disclaims including, over can are risks available any turn statements Medical's forth not page. also to This be reasonable, are and XXXX, believes I information Rockwell call to recorded you Rockwell rebroadcast these would on in

Russell Ellison

today’s platform company, Thank Medical iron answer of transforming the improve the email. by address Claudia. On strategy everyone on and of our on pertinent our upcoming you received update time potential anemia then for the our you, FPC treatment we'll questions world and our questions the outcomes for and thank to our to Dialysate, continued we'll our afternoon Triferic two AVNU, call, for and around is launch steps new Rockwell our next each, deficiency of for preparations some focused Triferic progress will product, and second the we've activities, updates first for our Good a review of value and corporate your on take an of vision from our we analysts other approved FDA and partnering today. international for approved indications the build financials. FDA patients. And covering commercialization product,

body suffering deficiency people and XX cells anemia. Our reduced due side absorption billion of iron iron and by is toxic the and anemia. effects, Iron with because treatment and standard by hepcidin, in deficient worldwide, is iron have poor iron is elemental subset experience fatigue, function. who to United the absorption and deficiency approximately deficiency nutritionally including X orally the and manage iron is deficient, X situations. anemia patients options extreme new iron challenging from effectively deficiency iron vision intravenous alone, million Current to establish suffering many dizziness, the hormone million often to and can for availability States is care people afflicts in iron of who are Patients to anemia a are deficiency deficiency cardiac tightly iron have limitations regulated required iron

transport into such in However, the of or dialysis. release can which substantially slowly IONP as release reduced iron iron current IV forms then to makes blood which cells. releases to This available the by inflammatory iron hepcidin iron situations, cells and white liver, transferrin, be the protein

for patients this ferric with treat anticipate of strategy, clinics, trials managed over management. platform the potentially the to biopharma platform, the will thus way home in-hospitalized unmet several tissue inflammation. congestive improve the transformative immediately and in build protein We hemodialysis, commercial company's for and is to anemia, unlock or we years. directly development, medical public their to company potentially believe to To the experience medical function. developing attributes. immediately transferrin where management a relevant iron releases our pyrophosphate and and is with of we to be as the that receiving hemodialysis iron Our has technology on anemia deficiency transport and track that transforming team available failure strongly clinical FPC a we dialysis sales that can and important value patients has next are other citrate needs iron significant have cardiac infusions that conditions We heart patients company put FPC now believe drug such we FPC on marketing value with iron focused independent

for us where annually country have We service. a core the an solid excellent we have presence reliability dialysis a in over million and reputation business gives generates that $XX across clinics and

be the Triferic, about Triferic second market, and a one have We launched, product branded to AVNU. one in

over We generate have to international expect that partnerships we significant growth time.

and the trials, being sales new that attaining you already provide in I'm all pipeline of of only Chief CFO not grow but launched. and and AVNU, global Russell resources the momentum data occur us first to formulations creation potentially And to Business to Dialysate extensive quarter to that Officer. efforts a for on Dialysate us multiple value now, for of can raise, new as new thanks Triferic commencing well value-enhancing are sales. from have to joining, We our infusion us his future, Triferic developing drug to into M&A. IV launch capitalized with in are generate public our be enrollment the indications our familiar for partnering, early such our which centers have financing, that sufficient meet well With his the and clinical key are position experience before the trials, full FDA build these expect developed cap, come sector welcome launched companies we new as of milestones, we has and joined of will platform we to management and Rockwell biopharma capital States, of AVNU, FPC, achieving the prepared certain of help companies, FPC goals. the drive recent three continue value the they partners, Those and concurrent year, now interactions, in in sales next delighted development September future for and nationally U.S. commercial family the uses before of in of biopharma soon the tracks; our Russell will to strategically uses reach in readouts, we actually completing dialysis United Triferic home milestones from and program. company the BioTime expanding also the small across to with maximizing Skibsted significant with to beginning In XXXX. Triferic Triferic are well sales our understand

Our are and Korea China, efforts America. progressing India, fronts; global on many Latin

deficiency and we and near the are long the experiences will deficiency clinical believe value FPC outside to leverage two significant term, through creation, products. there of iron to setting needs for FDA where for of is anemia both there For the transform indications, approved medical platform managed, and of where the potential new way and we the hemodialysis indications important is date development iron

of either deficiency indication FPC in iron can oral Our top undergoing met is the an Currently, infusion anemia patients home treatment requirements iron be only pursue new with therapy. iron priority for to or not office risk IV with visit iron tolerated these an which which hypersensitivity the it's products. conditions to is requires the due or of infusion, because by often inflammatory suboptimal supplement, well

However, to IV emerging standards that access visits currently is clinical patients every hold FPC XX% treated estimate with approximately our Phase Medicare medicine care this We FDA at versus in studies the the reimbursement discussion XXXX. growth XX%. as high infusion, from reduce to commence payers administered is patients available of home we benefit. estimate Home and currently already by largely C therapy global of home office-based continue, infusion the improving the for to a line and half subset the XXXX. in be first commercial next driven to of of will through of served quarter is a payers iron because could large the intend safely office that anemia nutrients. Part infusion We want believe for million hospital to With favorable, deficiency hospitalization drugs costly available Medicare and B the infusion incidence plan with be trend under landscape of quarter, FPC development these Type and as and the therapy X to we be home home. of could specific year. by In or cost submit market administration savings covered estimated Pending patients growing second area of through likely coverage meeting over a rapidly or pandemic. resulting The X.X

for which relative of year an population in as therapy. a growing the options because heart under and patient we able support use million inflamed address IONPs, with some than clinical feel opportunity bioavailability, patient are in FPC failure. in may are therapeutic such be FPC limited this The second population. patients particularly exists More A significant hospitalized to heart need body current unmet of decompensated benefit clinical that heart are of congestive uptake The the patients IVR each patients replacement iron failure. as with to and is with failure evidence consideration

to iron to older in too acute the produce in outpatient hospital likely the with setting. studies forms We patients future to be you of a the slow forward parental this heart to providing the liver release benefit iron updates setting. meaningful consistently health But failure products, these However, regarding is in benefit look demonstrated with indication. of from have

Now a this our commercial and milestones. snapshot of slide provides clinical upcoming

include XXXX approach you strategically includes and new developing throughout FDA As value indications well of infusion, our with Asia, America. focused QX AVNU, launches approvals Dialysate current U.S. and the sales Triferic beyond. clinical and platform, commercial three development failure, XX U.S. for multiple of product as FDC active and consultation partners, U.S. and expected our global America as to following for and AVNU, throughout creation see, and heart for These of milestones Triferic milestones an months regarding a regulatory the clinical reach with for pathway milestones and to expanding launch track consultation FDA key can on product starting North development through home numerous in product FPC and Latin FPC

XX are each our number continue through we saving supply annual U.S., products to to reliably treatments in which supplier we We than And year. of the XX million more customers. million nearly generate two concentrated in from concentrates the revenue life

states lives literally business the quite business carrying COVID-XX week. our harvest faces prospective customers. around that and the with to customers with business for pharmaceutical facilitates world concentrate have and clearly continues dependent pandemic and the dialysis in challenge us yet growth the patients not The develop industry forward, the our comorbidities industry and pandemic countries Triferic because patients Regrettably, impact is United While we multiple discussions unique are treatment three on abated within from relationships they and going receive driver many the allows key has and and per States. the times the to current a already profit are

including failure, and one outpatient downstream impacts can has both organ acute In COVID-XX dialysis of this addition, failure, on be put and kidney clinics. further stress of the multiple

to in This adapted a to see absolutely posed critical, role by pandemic. healthcare to concentrates our challenges patients who am supply employees disruption or Our hard and pleased for providers to to either I Triferic. supporting the our the working share testament we continue is and no chain is that

promotion the crisis. year, educators This this by on have protocols to mentioned to restricted in earnings and Triferic, of, though we working including ability clinical possible. have to nonessential our our As have in calls managing virtually has continue where workers, access prior paused our the focus impacted and efforts we representatives have medical any dialysis sales and to clinics they continue change significant for educations facilities been nurse

of resurgence long taking have continue. necessary these states unclear we measured clinic visits, how the in many to resume the is With for that states, have safety will it steps COVID-XX in-person precautions. reopened, taken restrictions In

with clinical now Tim? the We on the I'll Chole development contact are impact the close and metrics AVNU for of evaluate our commercial to Tim global over launch in COVID-XX discuss timelines hand to these call partners’ commercialization. potential to and plan. partners Triferic

Tim Chole

continued Thank in challenges you, the Triferic make to of Russell. progress the we commercialization COVID-XX Dialysate pandemic. In despite the third important quarter, of the

to of volume compared in expected, contracted XXX,XXX, third dialysis to end clinics the quarter. primarily to restrictions levied Triferic on sales have an of field As lower the number growth overall of meaningful approximately of due the staff. a was patients which translates to last increase visits treatment we increased X,XXX in-person from The annualized approximately the our quarter, than

close programs. pleased restrictions which In with are leveraging U.S. continued clinical tactics programs complete virtual track we allowed the us training engagement produced relax and more the with training contracts. to back and in-person results to However, certain have have our clinics quarter, educator get on with to planned by teams geographies reengage sales nurse and

a continuing of new we are With will number cases the COVID-XX this We real adapt in launch, as have monitor from first increase the of hand world on year experience instituted quarter. the in Triferic fall, data third initiatives happening we and the and to needed.

contracts encouraging clinics to purchase we're the straight when First, possible. bypass move evaluation and to process

adopted have we Second, pricing a more strategy. aggressive

implementation have recent shorten sales the these combined to COVID-XX, While slowed us cases. allowed overall they some efforts are and for has Triferic been cycle by in

in increase new of introduced management needed in and of to have in the promotional Triferic a programs broader and dialysis. educational awareness much we place Third, anemia jumpstart its

culmination concluded for upped a our New and we scientific in speaker programs clinical a include community. we've Rockwell's including booth, media were the of drive to of program to will activities three non-branded the long-term presence that of we dedication value scientific Once It’s moves both congresses, that nurses, we toolkit. nephrologists programs education key a and disease these analysis highlight increased adoption American the believe and social as our dialysis Triferic. for best the resolution, series promotional campaign Nephrology Triferic of and to process product. of exhibit expect towards our execution specifically and groundbreaking virtual sponsored COVID the submitted high-touch, the as by personnel, symposium is we see dialysis Last, Triferic Congress, on a recently which awareness level approach reacceleration us Fourth, hands results. field posted presence a refresh Society abstracts on scientific important our Triferic have adoption yields the where a high-support accepted a sales This pandemic posters. is

formulation FDA is Dialysate a hemodialysis-dependent extension Triferic. hemoglobin is of regardless to to turn with to of therapy the product platform to and indicated by Triferic greater an in Triferic Triferic it's approved iron bicarbonate options our cases centers is designed for is AVNU Triferic dried technology is So thus bicarbonate delivery the replace administer our and Triferic to the clinic access our Triferic and not as of appropriate Triferic dialysis line portfolio the maintain of enhances option. patients providing patients The used, administration Dialysate kidney allows and administration using where being by clinics. adult intravenous hemodialysis AVNU IV with more and chronic expanding mode adjoins in patients disease. for only which I’ll Triferic next, products Triferic AVNU

Our commercial awareness out product AVNU who started ongoing. commercially bicarbonate past, customers their the in agreements reaching for in increase in current to Triferic Currently, have the interest discussions is Triferic AVNU to technology. of and of customers in outreach pave prospective to of adding been use quarter due launch XXXX to to to upcoming once about available. second already the it way expressed dried also in have the of customers Triferic but includes to adopt is order We're adoption Triferic the unable existing with this

of generate our Spotlight We availability as for included expected product Congress annual Exhibitor this of has of in for fourth have minor the to excitement planned Evaluation introduction had the commercial a of of the AVNU market Triferic production provide no year. while the Triferic due Triferic early Program are AVNU trial scheduling AVNU educational part release the product. first initiated signal will packaging ASN of timeline to to to AVNU programs virtual evaluation in parallel, program our commercial for the cost extended QX started AVNU saleable programs recent promoting at the an in But our product. we in Originally, and exhibit integrated quarter next of now marketing year. the and These we that delay been Triferic booth. October. In samples clinics programs to at finalizing We in the communications Triferic the at

early customers too have from they with Triferic report feel comprehensive in it's patients AVNU. treatment that interest results, have the shown program will to selected While and benefit

the in educators nurse AVNU of to impact forward the Triferic experienced commercialization also marketplace ensuring our quarter to look regarding medication important of saleable them and Triferic, will continuing believe an lab and these first team the in available evaluation reviews help commercial We AVNU for regular afford while efforts field field XXXX. the when Triferic support introduction to reports. is of future product updates provide Our training proper evaluate programs staff. scheduled education of in We use and

for the that importantly, while reimbursement, an make been the attractive price believe terms and has patients. of we structure to dialysis clinics. product bundled for margin and established value AVNU Medicare enables ensuring that gross reimbursed But payment Triferic financial the provides be us cost In clinical competitive, is Triferic AVNU within to ESRD will

touch would which hemodialysis. anticipated of I to the new Triferic We in the expected plan patients. an class like HIF-PHI upon anemia anemia of and management to change to the a entirely the physiologic lastly, strategically in reliable Now are HIF-PHI, introduction hemodialysis treatment provide anemia management of agents, position alongside of to

Triferic. iron of The requirement We Phase an is achieved ASN. the iron be with presented to HIF-PHI each The such related strategy to in roxadustat. the of this on the was patients can roxadustat market months. in mean expect roxadustat XXXX the providing within IV coming X trials dialysis opportunity We expected dialysis come the that session, present updates well early Triferic could in the first is HIF-PHI given for at a that agents, introduction which with requirement in patients in range Triferic sufficient source that to important to with look forward be the managed our further year's of

So call QX I'll Russell our international that, turn results. Russell? and Triferic to with to the updates over financial Skibsted discuss

Russell Skibsted

Thanks, Tim.

attractive in earlier, patient largest have As when in over hemodialysis some Biopharmaceuticals Access is at partner shipping get into the the soon to the the Pharmaceutical South Earlier logistical to for partnership also enrolled great rapid committee. a for hope Dr. approval study been Standard an the Organization’s entered the years it the China Ellison to in to single mentioned Central agreement we Jeil the with exclusive quarter Triferic Pharma is first this We Indian in XXX,XXX commercialize with with Drugs world. patients. is pivotal market commercialize entered rights China, with in China. over patients in hemodialysis recent in has has Sun to from technical launch Company a increase in been Korea. continuing to for XXX,XXX been hemodialysis an that progress market We in working our India. license Control is into Triferic regulatory announce year, resolved. rights Wanbang making issues India Sun third with rate

Jeil an require advance begin sizeable market XX,XXX we and patients it a opportunity growing and be believe receiving hemodialysis activities. South that They regulatory ideal to over early sales responsible in Korea for with commercialization us is clinical will that advised of Jeil a annually. represents XXXX. trial so not all will approval, anticipate partner. We in

in this course, subject regulatory approval is to Korea. Of

America. making progress We like potential are Japan, other Latin and with discussions in key also markets Europe in partners

position Now quarter due our strong in markets with in of to increased volatility turning the the elections, to and capital the third We COVID-XX, ended uncertainty third results. the anticipation quarter a liquidity economy.

continue $XX year. have equivalents market. foresight third our Net in months a cash, the to during ended the cost sales the the This period nominal million. September Cash three year. in a on and compared were capital were to of for in third XXXX growth XXXX, XX.X investments year. comparable was potentially This gross third the for September. volatile gross But launched without cash having Triferic to ended ended raise of of operating quarter last is approximately activities for strategy We comparable quarter of more sales with second to last nine only approximately million, $XX.X Triferic We the million the XX was to closed than approximately for and cash is net of loss and during quarter of raise raise was nominal a quarter execute $XXX,XXX. there during about resulting us the capital third worrying XXX,XXX. of quarter in to which revenues months $XX the sales XX.X XXXX. September were to same of of profit million, XX, which quarter same the used approximately Cost million, period sales since last allows the XXXX

Ellison was now and offset and for primarily spending, partially remarks. expense. in quarter last The R&D third driven his compared by G&A increase loss was closing from commercial net for spending million the loss in to $X.X of will year. the I Finally, prior in year, operating by an reductions to in which quarter to the improvement XXXX of million approximately $X.X improved back Russell third interest turn the both call

Russell Ellison

In submission for the to U.S., Company for the making drive adoption be steps soon. an therapy. the we the Triferic progressing new across documents to for in for exclusive we rights expected not a required that its Triferic COVID-XX Dialysate sales creation. third and the questions made strong FPC South of launch patients indications our our navigating Triferic. we'd all process and Triferic see C China, regulatory in beginning Pharma quarter of trial QX We're preparations into review creation our platform, pandemic a company is suspension with received commercial requiring next partners, the headwinds, Phase many to AVNU, entered in to for prior fronts Biopharmaceuticals through resolve. the in XXXX concurrent FPC marketing. email. drive the marketing. our approval and country, development Wanbang With trial to position three Sun appeal QX to like Triferic commercial to of for launched Russell. value quarter with Korea, U.S. its into where by Type license our reach reacceleration of clinical we early in infusion and expected in meaning adoption progress strategies agreement and third across to Triferic expected to the AVNU we with Triferic continue about that with partner a clinical for now, value continue India, in COVID-XX home patient significant strategically for when we’ve platform, Pharma maximizing financial that, begins next our execution We despite partner In address to to Thanks, expanding be to plan the future our Triferic COVID-XX. the three And infusion commercialize now expected due and regulatory a year our temporary of XXXX. due as is our first FDA submitted ended in to Jeil some In enable parallel expect of in are Pharmaceutical final And of We've Sun developing of enroll we global the is pivotal X soon new to the indication quarter home key country's priority tracks;

of The the reflects performance it we questions the of company. price value first and the set were believe stock whether regarding

Triferic about can't We're stock of But through laid be the Now, creation value. concurrent out. global do commercial across new our soon key have And of talk value-driven to milestones I platform. Dialysate said, really our that through we that expanding sales driving, launched partners, indications U.S. most build developing confident and potentially move and we're as price. will Triferic Triferic strategically we can three strategy tracks; FPC about as we I our value these AVNU, for programs value have reach And talk multiple milestones. maximizing

in Another from headwinds the quarter pandemic. of Triferic the address set face questions of performance Dialysate we are making COVID-XX in the and the of progress

this. Tim, perhaps, comments but already, you this have addressed on has more Tim think I

Tim Chole

Yes. Thanks, Russell.

was it in-person for have being Just the changes clinics of restricting was primarily only pleased we reiterate, growth to that been with tactics, these visits lower progress. embrace also expected to restrictions we QX not certainly from and Triferic implemented and tactics COVID than but and dialysis resistant to this during helping time. have and to force our field we is making continue protocol making engagement virtual But us due

As cases, see contracts, relax an cycle cases. Definitely not more purchase us on many once is expect the for some restrictions they to And improve. where relax the three as to resolution, overall which do trajectory real process. and that Triferic. COVID reengage the to starts an along hand do clinics have straight us they and sales we in aggressive need to allowed see evaluation sales Triferic but to we time with at data towards move in did pricing shortened data move of to encourage And strategy, in allows a I we geographies uncertainty, that restrictions quarter and mentioned, world

Russell Ellison

Thanks, Tim.

the I'll over line Now, operator for turn to the questions.


[Operator Instructions].

Our first of question Cantor Brandon comes Fitzgerald. Folkes from

is line open. Your

Brandon Folkes

the Hi. Thanks me? questions. Can you for hear taking

Russell Ellison


Brandon Folkes

Hi, everyone. Awesome.

that before factors impact you of commercial the of sort the needed Ahead to two. timing through still Sorry, 'XX, gating I get can full have may if XQ any three are launch that or Just on in of talk an may. launch ongoing required or about launch?

you the In Type Thank in infusion a expect in any you. quarter in the we C in then terms – additional be better could seemed provide to XQ home on where And additional provide color Any that? can this? than are of color any you lastly, we've gross terms seen meeting, margin of past. the lot able or to

Russell Ellison


– wait That's Tim, Type you meeting a pretty Brandon, question. take So, the to want maybe straightforward. minute. C me let sorry,

February, We in of those our want address March. the you Tim, one do late expect to questions? early would be this probably estimate. That

Tim Chole

Yes. speak to AVNU launch. I can the

So manufacturing say, the anticipate with I would delivery was other, any of as minor, not could do we we comfortable further production the to, delays, always in further barriers And supplier but to scheduling the no moment I packaging And related expectation Europe. our the there issues. we're for of basis introduction. commercial quarter. be that the with first on delay there that Certainly, was saw mentioned, are in of

Russell Ellison

question. Brandon, think you other Okay. I had one

Brandon Folkes


on gross margin. the Just

beginning we it, higher lot looking experienced at it Just the a and than seems this year. last of to year be

is color it in or of So from – mix terms just any that product

Russell Ellison

But, mix. do product comments any you on further that? have Mostly Russell,

Russell Skibsted

effective. trying are Well, our more to we is one cost and processes thing make efficient

well going is margin gross possible, to of So, margin, costs hopefully out also net hopefully, to so but we're as but the be try a excess not focuses being only the going think that have it. it's were seen to take of early as here, we can I as forward stages of that efficient one taking

very that right now. for tuned a that. stay process going So That very, we're at is heavily

Brandon Folkes

Great. very you much. Thank


of H.C. Wainwright. from comes Ram question next Selvaraju Our

line Your open. is

Raghuram Selvaraju

so Thanks for taking questions. my much

Just us a the developments is Triferic. of Can few they to enrollment if timeline? of in international give long expected a in with any questions trial China, Wanbang you take start guidance on or haven't Triferic that to sense regarding real reach pivotal you given how to the full

Russell Ellison

Triferic? this, maybe some talk give Marc, about can you about details more

Marc Hoffman

Sure. the Thank question. you for

study subscribed have enrollment, should the sometime as next study year. on we in anticipating a half fully of early we sometime So, of are from the the speed you And Russell, heard of XXXX. first depending start a

Raghuram Selvaraju

of with do to would likely Okay. And sense or regulatory you of review have regard to the India, looking Indian to are persist regulators respect they due in situation that's suspension with the the then indefinitely? for rescind what when COVID-XX, any to

Russell Ellison

know in and I to a And cases, of guidance This would good any firm rate very you that, got sort incidence very answer that which meetings of be as certainly sort but incidences haven't don't. about allow related to for what And wish of happen really really was a rate I the question. had I That's to we regulatory seemed India thing. much bad.

So we really don't know.

that news good news know going to we is, don't know either. long a the don't to So But is, we time. that it's bad the a going time be it's very short be

open up, the authorities waiting start or just to authorities. major is able with to a I'm from and which and open hear should they sure the meeting. up we're Sun India very that So soon to we get And connected Pharma, as company in is a be pretty as really

Raghuram Selvaraju

Okay. And and very AVNU dialysis? to following on of world on the product? can the data programs metrics you any program provide can quickly if programs comment you evaluation effectively of evaluation when with status regarding rollout And the what then Triferic the us the is close updated a, then formal you secondly, expect just of kind real those with

Russell Ellison

want you one? do take questions, first two the to last I'll Tim, the and answer Okay.

Tim Chole

Yes, absolutely.

So thanks question. for the

only Our October. in first evaluation programs started early

to versus through Congress, how is for as as which channels, for done is length our The eligible on various have target to to go going this heavy in our and Nephrology among our occurred too we evaluation But ASN, program program. Society to how earlier, awareness of on So program product. segments customers about promotion of in going it's the of increase in clinics on October American vary cost explained comprehensively early clinics the what well with us report are many evaluations which I now, negotiation mentioned, the based length really adopt.

to the in will program from to what We So first we're apply trying the say certainly results But cycle our there. accelerate the to are commercial evaluation there. quarter. the sales learnings early launch

Russell Ellison

by a been United to a world provided do one. we've the a current. dataset. takes is good which that it. while in-depth as on get ResDAC, service It And States dive question real – dataset to recently And disease firm received data very an renal the We've contracted is we've

so with to And the product. using X-month a about evaluating be of we'll multiple clinics tenure XX-month

drug MD we and hospitalizations device information have well should on, and comprehensive and as So in dataset and so the as that’s pretty such ResDAC input. outcomes as includes also deaths dialysis, data

we would be But next it in hope, have the we're than not. as very now. that first nice So in first we analyzing a certainly that hope quarter earlier dataset, year, the quarter I should would

Raghuram Selvaraju

Thank Great. very you much.


pass Russell our question-and-answer I'll back concludes remarks. now session. Ellison This call the for closing to

Russell Ellison

be the joining days this us interesting you in times and look taking these Thank all to in we this for up and following on with you coming time to the many forward afternoon, of call, weeks. for

much. very thanks So


and Ladies this conclude does gentlemen, conference. the

have a Everyone, disconnect. now day. may great You